Janus Henderson Investors, Brahma Capital and BioTrack Capital led a $84m Series B funding round in BlossomHill Therapeutics.

Janus Henderson Investors, an asset manager, Brahma Capital, an investment firm, and BioTrack Capital, a venture capital firm, led a $84m Series B funding round in BlossomHill Therapeutics, a biotechnology company developing cancer medicines, with participation from Cormorant Asset Management, OrbiMed Advisors, Plaisance Capital Management, and Vivo Capital. “With clinical data beginning to come into focus across both of our lead programs, momentum is building at BlossomHill Therapeutics. We are delighted by the strong vote of confidence from new and existing investors in this financing, which arrives at a critical juncture as we drive our clinical programs forward and leverage our established track record in oncology drug design to address the challenges of cancer treatment resistance and deliver meaningful benefit for cancer patients,” J. Jean Cui, BlossomHill Therapeutics President & CEO.